Indivior Pharmaceuticals tops Q3 revenue estimates, net income hits record

Supernus

29/10/2026 11:16

Overview
US addiction treatment maker's Q3 revenue rose 13% year-over-year
Company posted record net income and non-GAAP net income in Q3
Company expects to close merger with Supernus on November 2

Outlook
Company expects FY 2026 net revenue of $1.295 bln to $1.365 bln
Indivior forecasts FY 2026 SUBLOCADE net revenue of $1.01 bln to $1.05 bln
Company sees FY 2026 adjusted EBITDA between $700 mln and $740 mln

Result Drivers
SUBLOCADE VOLUME AND PRICING - Co said 24% growth in SUBLOCADE revenue was driven by higher dispense unit volume and favorable price/mix and gross-to-net adjustments
LOWER OPERATING EXPENSES - Co attributed improved profitability to reduced GAAP and non-GAAP operating expenses
CASH GENERATION - Co said strong cash generation contributed to financial strength

Company press release: ID:nGNX1CrFxm

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$356 mln
$329.35 mln (2 Analysts)
Q3 Adjusted EPS
Beat
$1.32
$1.12 (2 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Indivior Pharmaceuticals Inc is $50.00, about 43.8% above its October 28 closing price of $34.77
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 14 three months ago

Reuters Recommended Reads
Oct 29 - Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Oct 29 - Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)